Second-line treatment with a combination of bevacizumab plus the chemotherapies carboplatin and pegylated liposomal doxorubicin may significantly improve the outcomes of platinum-sensitive ovarian cancer patients, compared to standard treatment, findings from a Phase 3 trial suggest. Women who received this experimental combination in the ENGOT-ov18 trial (NCT01837251) lived significantly longer without disease progression and experienced extended overall survival than those on standard bevacizumab, carboplatin, and gemcitabine, all without impairing quality of life. The findings were…
You must be logged in to read/download the full post.
The post Liposomal Doxorubicin-based Regimen Improves Outcomes in Platinum-sensitive Ovarian Cancer appeared first on BioNewsFeeds.